Shop

Author at Microdose

Microdose NewsDesk

Microdose's editorial department brings you the latest news and industry insights.

Don’t Miss

30 Jan 2023

News You Might Have Missed: Jan 30th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

27 Jan 2023

Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific

Irwin Naturals Signs Letter of Intent to Acquire Braxia Scientific...

By Microdose NewsDesk

Industry

25 Jan 2023

Small Pharma Reports Positive Results from Phase IIa DMT Trial

Big news as Small Pharma has announced positive topline results for its Phase 2a trial using DMT for depression....

By Microdose NewsDesk

Industry

24 Jan 2023

Health Canada Approves Diamond Therapeutics’ Phase 2 Trial of Low-Dose Psilocybin

Diamond Therapeutics Phase 2 trial has been approved by Health Canada, a four-week, Phase 2 randomized, double-blind study in adult patients with Generalized Anxiety Disorder...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Industry

20 Jan 2023

Mindset Granted Patent for Lead Drug (But Reunion Also Has Patent)

Mindset Pharma has been granted a U....

By Microdose NewsDesk

Industry

18 Jan 2023

Cybin Announces Promising Results From Study Measuring Psychedelic Effects on the Brain

Cybin Announces Promising Results from Kernel Flow® Study Measuring Psychedelic Effects on the Brain...

By Microdose NewsDesk

Industry

17 Jan 2023

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Algernon Pharmaceuticals subsidiary, Algernon NeuroScience, has dosed the first subject in its Phase 1 clinical study of an intravenous formulation of DMT in the Netherlands....

By Microdose NewsDesk

Don’t Miss

16 Jan 2023

News You Might Have Missed: Jan 16th, 2023

Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed....

By Microdose NewsDesk

Industry

12 Jan 2023

Cybin Selects Generalized Anxiety Disorder for DMT Drug CYB-004

Cybin has selected Generalized Anxiety Disorder as the target indication for its proprietary deuterated N, N-dimethyltryptamine DMT program CYB004....

By Microdose NewsDesk

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

You Might Also Like

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts

15 Oct 2025

The IP Battle Behind the $1.2B Psychedelic Acquisition—and Why Enveric Biosciences Is a Name to Watch

Take Enveric Biosciences (NASDAQ: ENVB), a company that’s been flying under the radar while building an IP fortress around a novel class of non-hallucinogenic neuroplastogens. Now, that fortress is being...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.